Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-10

AUTHORS

Amir Mehrvarz Sarshekeh, Henry Q. Xiong, Kenzo Iizuka, Howard S. Hochster, Scott Kopetz

ABSTRACT

Background DFP-10917 is a cytotoxic deoxycytidine analogue that causes DNA fragmentation, G2/M-phase arrest, and apoptosis. This agent has been shown to have antitumor activity against colorectal cancer (CRC) in preclinical studies and to be tolerable in patients. The purpose of our phase II trial was to evaluate the safety, efficacy and pharmacogenomics of DFP-10917 as well as DNA damage studies in patients with advanced CRC refractory to cytotoxic chemotherapy. Methods In this single-arm, Simon two-stage, phase II trial, patients with chemotherapy-refractory advanced CRC received 2.0 mg/m2/day DFP-10917 via 14-day continuous infusion. Enrollment criteria included age ≥ 18 years, Eastern Cooperative Oncology Group status of 0 or 1, and adequate organ function. The primary endpoint was 3-month progression-free survival, defined as the proportion of patients who did not have progressive disease or death within 3 months of starting therapy. All patients who received any amount of DFP-10917 were included in the safety analysis. DNA damage study was assessed by comet assay. Results Of 28 patients initially enrolled, 26 received DFP-10917. Three patients (12%) were progression free at 3 months. The median progression-free survival was 1.3 months (95% confidence interval, 1.3-1.6 months). There were no complete or partial responses. Most patients (n = 20, 77%) had progressive disease, and only six (23%) had stable disease at any time. The trial was terminated according to the pre-planned stopping rule. The most frequent (≥5%) medication-related grade 3 or higher adverse events were neutropenia (n = 10, 38%), fatigue (n = 4, 15%), anemia (n = 3, 12%), and leukopenia (n = 3, 12%). DNA strand-breaks were detected after infusion (medians of % tail intensity were 2.89 and 12.64 on day 1 and day 15, respectively, p < 0.001, sign test). Conclusion Overall, single-agent DFP-10917 did not show meaningful antitumor activity in chemotherapy-refractory advanced CRC. The safety profile of DFP-10917 was tolerable and similar to that observed in earlier clinical studies. More... »

PAGES

895-902

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-018-0615-8

DOI

http://dx.doi.org/10.1007/s10637-018-0615-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104555840

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29948357


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mehrvarz Sarshekeh", 
        "givenName": "Amir", 
        "id": "sg:person.010265152253.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010265152253.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Cancer and Blood Disorders", 
          "id": "https://www.grid.ac/institutes/grid.477919.5", 
          "name": [
            "The Center for Cancer and Blood Disorders, Fort Worth, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xiong", 
        "givenName": "Henry Q.", 
        "id": "sg:person.016444546257.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016444546257.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Delta-Fly Pharma Inc., Tokushima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iizuka", 
        "givenName": "Kenzo", 
        "id": "sg:person.014677065052.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014677065052.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rutgers University", 
          "id": "https://www.grid.ac/institutes/grid.430387.b", 
          "name": [
            "Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hochster", 
        "givenName": "Howard S.", 
        "id": "sg:person.01245075433.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245075433.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kopetz", 
        "givenName": "Scott", 
        "id": "sg:person.01320500077.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320500077.48"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1414325", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002050137"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/mutage/18.1.45", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003832825"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1097-0215(19990719)82:2<226::aid-ijc13>3.0.co;2-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010731481"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)61900-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020430219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1349-7006.2004.tb03189.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022841073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1349-7006.2004.tb03189.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022841073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032745321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000180580", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051087304"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(89)90015-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053744925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(89)90015-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053744925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm00017a023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055932714"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm00078a006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055934358"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2307/2530286", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069975816"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2307/3577587", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070380221"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/mol.59.4.725", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074786450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.26.15_suppl.2577", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079371609"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082989737", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.2018.4246", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100441151"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10", 
    "datePublishedReg": "2018-10-01", 
    "description": "Background DFP-10917 is a cytotoxic deoxycytidine analogue that causes DNA fragmentation, G2/M-phase arrest, and apoptosis. This agent has been shown to have antitumor activity against colorectal cancer (CRC) in preclinical studies and to be tolerable in patients. The purpose of our phase II trial was to evaluate the safety, efficacy and pharmacogenomics of DFP-10917 as well as DNA damage studies in patients with advanced CRC refractory to cytotoxic chemotherapy. Methods In this single-arm, Simon two-stage, phase II trial, patients with chemotherapy-refractory advanced CRC received 2.0\u00a0mg/m2/day DFP-10917 via 14-day continuous infusion. Enrollment criteria included age\u00a0\u2265\u00a018\u00a0years, Eastern Cooperative Oncology Group status of 0 or 1, and adequate organ function. The primary endpoint was 3-month progression-free survival, defined as the proportion of patients who did not have progressive disease or death within 3\u00a0months of starting therapy. All patients who received any amount of DFP-10917 were included in the safety analysis. DNA damage study was assessed by comet assay. Results Of 28 patients initially enrolled, 26 received DFP-10917. Three patients (12%) were progression free at 3\u00a0months. The median progression-free survival was 1.3\u00a0months (95% confidence interval, 1.3-1.6\u00a0months). There were no complete or partial responses. Most patients (n\u2009=\u200920, 77%) had progressive disease, and only six (23%) had stable disease at any time. The trial was terminated according to the pre-planned stopping rule. The most frequent (\u22655%) medication-related grade 3 or higher adverse events were neutropenia (n\u2009=\u200910, 38%), fatigue (n\u2009=\u20094, 15%), anemia (n\u2009=\u20093, 12%), and leukopenia (n\u2009=\u20093, 12%). DNA strand-breaks were detected after infusion (medians of % tail intensity were 2.89 and 12.64 on day 1 and day 15, respectively, p\u2009<\u20090.001, sign test). Conclusion Overall, single-agent DFP-10917 did not show meaningful antitumor activity in chemotherapy-refractory advanced CRC. The safety profile of DFP-10917 was tolerable and similar to that observed in earlier clinical studies.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-018-0615-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5475983", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438826", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "name": "Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer", 
    "pagination": "895-902", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "6e25190c64d05dcf260a61986500f9d9e8da1df30af25dd9875c8e87063fb963"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29948357"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-018-0615-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104555840"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-018-0615-8", 
      "https://app.dimensions.ai/details/publication/pub.1104555840"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78947_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10637-018-0615-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0615-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0615-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0615-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0615-8'


 

This table displays all metadata directly associated to this object as RDF triples.

159 TRIPLES      21 PREDICATES      46 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-018-0615-8 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N278bdece8648450c9153ecca928c16d4
4 schema:citation https://app.dimensions.ai/details/publication/pub.1082989737
5 https://doi.org/10.1002/(sici)1097-0215(19990719)82:2<226::aid-ijc13>3.0.co;2-x
6 https://doi.org/10.1016/0197-2456(89)90015-9
7 https://doi.org/10.1016/s0140-6736(12)61900-x
8 https://doi.org/10.1021/jm00017a023
9 https://doi.org/10.1021/jm00078a006
10 https://doi.org/10.1056/nejmoa1414325
11 https://doi.org/10.1093/jnci/92.3.205
12 https://doi.org/10.1093/mutage/18.1.45
13 https://doi.org/10.1111/j.1349-7006.2004.tb03189.x
14 https://doi.org/10.1124/mol.59.4.725
15 https://doi.org/10.1159/000180580
16 https://doi.org/10.1200/jco.2008.26.15_suppl.2577
17 https://doi.org/10.2307/2530286
18 https://doi.org/10.2307/3577587
19 https://doi.org/10.3322/caac.21332
20 https://doi.org/10.3892/ijo.2018.4246
21 schema:datePublished 2018-10
22 schema:datePublishedReg 2018-10-01
23 schema:description Background DFP-10917 is a cytotoxic deoxycytidine analogue that causes DNA fragmentation, G<sub>2</sub>/M-phase arrest, and apoptosis. This agent has been shown to have antitumor activity against colorectal cancer (CRC) in preclinical studies and to be tolerable in patients. The purpose of our phase II trial was to evaluate the safety, efficacy and pharmacogenomics of DFP-10917 as well as DNA damage studies in patients with advanced CRC refractory to cytotoxic chemotherapy. Methods In this single-arm, Simon two-stage, phase II trial, patients with chemotherapy-refractory advanced CRC received 2.0 mg/m<sup>2</sup>/day DFP-10917 via 14-day continuous infusion. Enrollment criteria included age ≥ 18 years, Eastern Cooperative Oncology Group status of 0 or 1, and adequate organ function. The primary endpoint was 3-month progression-free survival, defined as the proportion of patients who did not have progressive disease or death within 3 months of starting therapy. All patients who received any amount of DFP-10917 were included in the safety analysis. DNA damage study was assessed by comet assay. Results Of 28 patients initially enrolled, 26 received DFP-10917. Three patients (12%) were progression free at 3 months. The median progression-free survival was 1.3 months (95% confidence interval, 1.3-1.6 months). There were no complete or partial responses. Most patients (n = 20, 77%) had progressive disease, and only six (23%) had stable disease at any time. The trial was terminated according to the pre-planned stopping rule. The most frequent (≥5%) medication-related grade 3 or higher adverse events were neutropenia (n = 10, 38%), fatigue (n = 4, 15%), anemia (n = 3, 12%), and leukopenia (n = 3, 12%). DNA strand-breaks were detected after infusion (medians of % tail intensity were 2.89 and 12.64 on day 1 and day 15, respectively, p &lt; 0.001, sign test). Conclusion Overall, single-agent DFP-10917 did not show meaningful antitumor activity in chemotherapy-refractory advanced CRC. The safety profile of DFP-10917 was tolerable and similar to that observed in earlier clinical studies.
24 schema:genre research_article
25 schema:inLanguage en
26 schema:isAccessibleForFree false
27 schema:isPartOf N0e4c3db74ba5439fb95ccba5184f8a51
28 Nf0c554861f484c4a857bcdff53d0fcf2
29 sg:journal.1094201
30 schema:name Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer
31 schema:pagination 895-902
32 schema:productId N1a9c7b1d087c47af9a97604432493465
33 N3c012cd1997344fa91bb7f2e5ef0857e
34 N72e35bf8c68547d39cf05f96dd87142b
35 Nca5db2cc88ef4d578a923e5b792c3059
36 Ndbcf6fd10f9b456b97642c971d884c63
37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104555840
38 https://doi.org/10.1007/s10637-018-0615-8
39 schema:sdDatePublished 2019-04-11T13:18
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher Nf32c9e94be9e44cf9fb3f70a0fa2de61
42 schema:url https://link.springer.com/10.1007%2Fs10637-018-0615-8
43 sgo:license sg:explorer/license/
44 sgo:sdDataset articles
45 rdf:type schema:ScholarlyArticle
46 N0e4c3db74ba5439fb95ccba5184f8a51 schema:issueNumber 5
47 rdf:type schema:PublicationIssue
48 N135efdd94878486cbc3a5c7eb8ee6530 rdf:first sg:person.016444546257.55
49 rdf:rest Nc01cfae6f7e647fa9e55c955372d769a
50 N1a9c7b1d087c47af9a97604432493465 schema:name nlm_unique_id
51 schema:value 8309330
52 rdf:type schema:PropertyValue
53 N278bdece8648450c9153ecca928c16d4 rdf:first sg:person.010265152253.88
54 rdf:rest N135efdd94878486cbc3a5c7eb8ee6530
55 N3c012cd1997344fa91bb7f2e5ef0857e schema:name readcube_id
56 schema:value 6e25190c64d05dcf260a61986500f9d9e8da1df30af25dd9875c8e87063fb963
57 rdf:type schema:PropertyValue
58 N72e35bf8c68547d39cf05f96dd87142b schema:name pubmed_id
59 schema:value 29948357
60 rdf:type schema:PropertyValue
61 N8aa164856a5340e19aaa552b31e55b0e rdf:first sg:person.01245075433.32
62 rdf:rest Nc1602d25f8f14dbfa200b5fb639d4a60
63 Nc01cfae6f7e647fa9e55c955372d769a rdf:first sg:person.014677065052.45
64 rdf:rest N8aa164856a5340e19aaa552b31e55b0e
65 Nc1602d25f8f14dbfa200b5fb639d4a60 rdf:first sg:person.01320500077.48
66 rdf:rest rdf:nil
67 Nca5db2cc88ef4d578a923e5b792c3059 schema:name doi
68 schema:value 10.1007/s10637-018-0615-8
69 rdf:type schema:PropertyValue
70 Ndbcf6fd10f9b456b97642c971d884c63 schema:name dimensions_id
71 schema:value pub.1104555840
72 rdf:type schema:PropertyValue
73 Nf0c554861f484c4a857bcdff53d0fcf2 schema:volumeNumber 36
74 rdf:type schema:PublicationVolume
75 Nf32c9e94be9e44cf9fb3f70a0fa2de61 schema:name Springer Nature - SN SciGraph project
76 rdf:type schema:Organization
77 Nf88c475e1f19431facba85aa68959305 schema:name Delta-Fly Pharma Inc., Tokushima, Japan
78 rdf:type schema:Organization
79 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
80 schema:name Medical and Health Sciences
81 rdf:type schema:DefinedTerm
82 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
83 schema:name Oncology and Carcinogenesis
84 rdf:type schema:DefinedTerm
85 sg:grant.2438826 http://pending.schema.org/fundedItem sg:pub.10.1007/s10637-018-0615-8
86 rdf:type schema:MonetaryGrant
87 sg:grant.5475983 http://pending.schema.org/fundedItem sg:pub.10.1007/s10637-018-0615-8
88 rdf:type schema:MonetaryGrant
89 sg:journal.1094201 schema:issn 0167-6997
90 1573-0646
91 schema:name Investigational New Drugs
92 rdf:type schema:Periodical
93 sg:person.010265152253.88 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
94 schema:familyName Mehrvarz Sarshekeh
95 schema:givenName Amir
96 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010265152253.88
97 rdf:type schema:Person
98 sg:person.01245075433.32 schema:affiliation https://www.grid.ac/institutes/grid.430387.b
99 schema:familyName Hochster
100 schema:givenName Howard S.
101 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245075433.32
102 rdf:type schema:Person
103 sg:person.01320500077.48 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
104 schema:familyName Kopetz
105 schema:givenName Scott
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320500077.48
107 rdf:type schema:Person
108 sg:person.014677065052.45 schema:affiliation Nf88c475e1f19431facba85aa68959305
109 schema:familyName Iizuka
110 schema:givenName Kenzo
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014677065052.45
112 rdf:type schema:Person
113 sg:person.016444546257.55 schema:affiliation https://www.grid.ac/institutes/grid.477919.5
114 schema:familyName Xiong
115 schema:givenName Henry Q.
116 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016444546257.55
117 rdf:type schema:Person
118 https://app.dimensions.ai/details/publication/pub.1082989737 schema:CreativeWork
119 https://doi.org/10.1002/(sici)1097-0215(19990719)82:2<226::aid-ijc13>3.0.co;2-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1010731481
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1016/0197-2456(89)90015-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053744925
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1016/s0140-6736(12)61900-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1020430219
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1021/jm00017a023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055932714
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1021/jm00078a006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055934358
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1056/nejmoa1414325 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002050137
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1093/mutage/18.1.45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003832825
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1111/j.1349-7006.2004.tb03189.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1022841073
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1124/mol.59.4.725 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074786450
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1159/000180580 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051087304
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1200/jco.2008.26.15_suppl.2577 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079371609
142 rdf:type schema:CreativeWork
143 https://doi.org/10.2307/2530286 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069975816
144 rdf:type schema:CreativeWork
145 https://doi.org/10.2307/3577587 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070380221
146 rdf:type schema:CreativeWork
147 https://doi.org/10.3322/caac.21332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032745321
148 rdf:type schema:CreativeWork
149 https://doi.org/10.3892/ijo.2018.4246 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100441151
150 rdf:type schema:CreativeWork
151 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
152 schema:name Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
153 rdf:type schema:Organization
154 https://www.grid.ac/institutes/grid.430387.b schema:alternateName Rutgers University
155 schema:name Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
156 rdf:type schema:Organization
157 https://www.grid.ac/institutes/grid.477919.5 schema:alternateName Center for Cancer and Blood Disorders
158 schema:name The Center for Cancer and Blood Disorders, Fort Worth, TX, USA
159 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...